Results 81 to 90 of about 3,839 (199)

Experiences From the First Year of Using Garadacimab to Treat Hereditary Angioedema and Acquired Angioedema

Clinical and Translational Allergy, Volume 16, Issue 10, October 2026.
ABSTRACT Background Garadacimab, a first‐in‐class, recombinant monoclonal antibody targeting activated FXII, is available in Germany for long‐term prophylaxis (LTP) of hereditary angioedema (HAE) since March 2025. We aimed to examine garadacimab real‐life treatment outcomes at our Berlin Angioedema Center of Reference and Excellence (ACARE), the ...
Markus Magerl, Kathrin Schön, Janine Ruhe, Felix Aulenbacher, Leonie Shirin Herzog, Thomas Buttgereit   +5 more
wiley   +1 more source

Intraprocedural Hemodynamics During Concomitant Rheocarna Therapy and Maintenance Hemodialysis: Effects of Dialyzer Membrane Type and Circuit Sequence

Journal of Clinical Apheresis, Volume 41, Issue 5, October 2026.
ABSTRACT Chronic limb‐threatening ischemia (CLTI), a severe manifestation of peripheral artery disease, is particularly prevalent among patients receiving maintenance hemodialysis (HD) and is associated with poor limb and survival outcomes. Low‐density lipoprotein (LDL) apheresis, including Rheocarna, is used as adjunctive therapy for refractory CLTI ...
Yusuke Ishizuka, Genshin Sato, Shizuka Ishigaki, Ryo Enoki, Kako Kajiwara, Akihiko Nakasato, Sosuke Kinomura, Saori Kin, Yuji Noguchi, Daisuke Yoshizawa, Koichi Kikuchi, Michiaki Abe, Koki Kumagai, Tetsuhiro Tanaka, Koji Okamoto   +14 more
wiley   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, Volume 270, Issue 2, Page 139-162, October 2026.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

Dipeptidyl Peptidase‐4 Inhibitor Use and Risk of Pemphigus Vulgaris and Foliaceus: A Retrospective Cohort Study Using Databases of the Korea National Health Insurance Claims and the National Health Screening Examination

The Journal of Dermatology, Volume 53, Issue 10, Page 1429-1438, October 2026.
ABSTRACT Although population‐based studies have reported an increased risk of bullous pemphigoid and pemphigus associated with dipeptidyl peptidase‐4 (DPP‐4) inhibitors, there is limited, well‐designed epidemiological evidence for pemphigus vulgaris (PV), which has only been supported by case reports thus far.
Jaein Lee, Jae Hyun Bae, Seokyung Hahn
wiley   +1 more source

Human Allergy to Cats and Dogs: Molecular and Environmental Determinants, Diagnosis, and Precision Management

Veterinary Sciences
Cat- and dog-derived allergenic proteins are important indoor exposure sources, but allergen exposure, IgE sensitization, and clinically manifest allergy are distinct biological and clinical states.
Jungwhan Chon, Kun-Ho Seo, Yeonghun Jee, Kihoon Kim, Kwang-Young Song   +4 more
doaj   +1 more source

Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.

PLoS ONE, 2009
Kallikreins-related peptidases (KLKs) are serine proteases and have been implicated in the desquamation process of the skin. Their activity is tightly controlled by epidermal protease inhibitors like the lympho-epithelial Kazal-type inhibitor (LEKTI ...
Ulf Meyer-Hoffert, Zhihong Wu, Jens-Michael Schröder   +2 more
doaj   +1 more source

Google searches show persistent use of outdated terminology for angioedema in Germany

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Sophia Neisinger, Thomas Buttgereit, Torsten Zuberbier, Markus Magerl   +3 more
wiley   +1 more source

mRNA Therapeutics for Skin Rejuvenation: From Aging Atlases to Clinical Translation

Experimental Dermatology, Volume 35, Issue 10, October 2026.
ABSTRACT Skin aging is a multifactorial process characterized by the progressive decline of tissue structure, function and regenerative capacity. Although numerous interventions have been developed to improve the clinical manifestations of aging, most primarily alleviate downstream consequences rather than directly targeting the molecular mechanisms ...
Fabiana Boncimino, Stefano Sol, Kristina Todorova, Anna Mandinova   +3 more
wiley   +1 more source

Proteomic profiling identifies candidate biomarkers for small intestinal neuroendocrine tumours G1 and G2

Journal of Neuroendocrinology, Volume 38, Issue 10, October 2026.
Abstract Although small intestinal neuroendocrine tumours (SI‐NET) Grade 1 (G1) and 2 (G2) are often studied together, clinical course and response to treatment may differ. We hypothesized that these tumour groups express different markers in blood that may inform future treatment strategies. Blood from 107 SI‐NET patients (G1 n = 64, G2 n = 43) and 50
Malin Grönberg, Dimitrios Papantoniou, Eva Tiensuu Janson   +2 more
wiley   +1 more source

Host‐Associated Differentiation in a Parasitoid Wasp Connected to Venom‐Related but Not Chemosensory Genes

Molecular Ecology, Volume 35, Issue 19, October 2026.
ABSTRACT The mechanisms driving the megadiversity of parasitic wasps remain a central question in evolutionary ecology. To investigate the genomic architecture underlying host‐associated differentiation in parasitic wasps, we generated a de novo genome assembly and performed whole‐genome re‐sequencing of 17 populations of the parasitoid wasp Asecodes ...
Xuyue Yang, Marco Fracassetti, Tanja Slotte, Christopher W. Wheat, Peter A. Hambäck   +4 more
wiley   +1 more source